Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

To date, the Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapy products targeting CD19 and BCMA for B-cell lymphomas, leukemias and multiple myeloma, ...

A growing body of research suggests that clinicians can offer chimeric antigen receptor (CAR) T-cell therapy safely and ...

The international Phase 1 study, called CARLYSE, is the first in the UK to assess the potential of CAR-T (Chimeric Antigen ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a study in Frontiers of Medicine has identified a pivotal role for CD39 ...

Scientists have devised new types of chimeric antigen-receptor (CAR) T cells -- a type of cancer immunotherapy -- that can be switched on to varying degrees of intensity and then switched off on ...